The “Stepping Stone” Approach to Getting Longevity Drugs to Market
Getting geroprotective drugs to market for specific disease applications is the first step in eventually making them available for healthier aging.
School of Shrooms
Oregon’s grand experiment in training psychedelic facilitators is facing a tangle of ambiguity and red tape.
Book Review: We the Scientists
How a daring team of parents and doctors forged a new path for medicine.
Squirrels Survive When Humans Would Die
Fauna Bio mines squirrel genomes for clues to developing new drugs for humans.
The Lure of Self Experimentation
These innovators are using their own bodies to build evidence for their hypotheses.
2023 Predictions—the Good, the Bad, and the Ugly
What to expect in genetic engineering, neuroscience, psychedelics, longevity research, digital health, food, human performance, wellbeing, and of course, ChatGPT.
AI Versus Antibiotic Resistance
AI can help overcome both scientific and financial hurdles to tackle this serious threat to global health.
Sarcopenia: What a Waste
Sarcopenia, a muscle wasting disease, could shorten your life and is alarmingly prevalent. Why are so many people unaware it exists?
Is Low-Dose Lithium a Better Solution for Major Depression?
Some studies show it’s better than SSRIs—but there’s no incentive to invest in clinical trials.